George Lau | Academic Influence

George Lau's AcademicInfluence.com Rankings

George Lau

Computer Science

#10684

World Rank

#11235

Historical Rank

Computational Linguistics

#2685

World Rank

#2714

Historical Rank

Machine Learning

#4869

World Rank

#4926

Historical Rank

Artificial Intelligence

#5237

World Rank

#5308

Historical Rank

computer-science Degrees

Download Badge

Computer Science

George Lau's Degrees

PhD Computer Science Stanford University
Masters Computer Science University of California, Berkeley
Bachelors Computer Science University of California, Berkeley

Similar Degrees You Can Earn

Why Is George Lau Influential?

(Suggest an Edit or Addition)

According to Wikipedia, George Lau is a specialist in gastroenterology and hepatology, currently the founder and chairman of the Humanity and Health Medical Group in Hong Kong. Contributions Hepatitis-free Generation Project Lau was the attending physician of the late "Godfather of Hong Kong" Music" Roman Tam . They became good friends. Lau initiated "Hepatitis-free Generation " project. Roman was involved in proposing the project name and claimed "These five words are easy to remember and catchy!" In order to promote the "Hepatitis-free Generation" Project, three major foundations including Cheng Si Yuan Hepatitis Research Foundation joined hands to hold a "Hepatitis-free Generation" event week at the end of November 2003. The highlight of the event was a large-scale charity concert held at the Capital Indoor Stadium, featuring many Chinese Pop singers from the Emperor Group. In 2016, Humanity and Health Medical group collaborated with the CSY Hepatitis Research Foundation, with the leadership and support of Liver Disease Experts was providing free Hepatitis B rapid testing, quick blood sugar testing and liver fibrosis scanning services for citizens on World Hepatitis Day. The aim was to raise public awareness of liver cancer prevention, early diagnosis, and detection of chronic liver disease, and to improve the cure rate of the disease.

(See a Problem?)

George Lau's Published Works

Number of citations in a given year to any of this author's works

Total number of citations to an author for the works they published in a given year. This highlights publication of the most important work(s) by the author

Published Works

Asian-Pacific clinical practice guidelines on the management of hepatitis B: a 2015 update (2015) (1728)
Peginterferon Alfa-2a, lamivudine, and the combination for HBeAg-positive chronic hepatitis B. (2005) (1285)
Peginterferon alfa-2a alone, lamivudine alone, and the two in combination in patients with HBeAg-negative chronic hepatitis B. (2004) (1118)
Asian-Pacific consensus statement on the management of chronic hepatitis B: a 2008 update (2008) (926)
Acute-on-chronic liver failure: consensus recommendations of the Asian Pacific Association for the study of the liver (APASL) (2009) (906)
Lansoprazole for the prevention of recurrences of ulcer complications from long-term low-dose aspirin use. (2002) (650)
Prediction for Progression Risk in Patients with COVID-19 Pneumonia: the CALL Score (2020) (514)
Early is superior to deferred preemptive lamivudine therapy for hepatitis B patients undergoing chemotherapy. (2003) (451)
Guidelines for the assessment and management of non‐alcoholic fatty liver disease in the Asia–Pacific region: Executive summary (2007) (443)
Hepatitis B virus surface antigen levels: A guide to sustained response to peginterferon alfa‐2a in HBeAg‐negative chronic hepatitis B (2009) (430)
Asian‐Pacific consensus statement on the management of chronic hepatitis B: a 2005 update (2005) (389)
Factors that predict response of patients with hepatitis B e antigen-positive chronic hepatitis B to peginterferon-alfa. (2009) (375)
Acute-on-chronic liver failure: consensus recommendations of the Asian Pacific association for the study of the liver (APASL): an update (2019) (360)
Non-alcoholic fatty liver diseases in patients with COVID-19: A retrospective study (2020) (350)
Hepatocellular carcinoma (HCC): a global perspective. (2010) (325)
Non‐alcoholic fatty liver disease in the Asia–Pacific region: Definitions and overview of proposed guidelines (2007) (318)
Sustained response of hepatitis B e antigen-negative patients 3 years after treatment with peginterferon alpha-2a. (2009) (317)
Human umbilical cord mesenchymal stem cells improve liver function and ascites in decompensated liver cirrhosis patients (2012) (308)
Predicting response to peginterferon α-2a, lamivudine and the two combined for HBeAg-negative chronic hepatitis B (2006) (280)
HBeAg and hepatitis B virus DNA as outcome predictors during therapy with peginterferon alfa‐2a for HBeAg‐positive chronic hepatitis B (2008) (247)
COVID-19: Discovery, diagnostics and drug development (2020) (233)
High hepatitis B virus (HBV) DNA viral load as the most important risk factor for HBV reactivation in patients positive for HBV surface antigen undergoing autologous hematopoietic cell transplantation. (2002) (213)
EASL International Consensus Conference on Hepatitis B. 13-14 September, 2002 Geneva, Switzerland. Consensus statement (long version). (2003) (204)
APASL consensus statements and recommendation on treatment of hepatitis C (2016) (193)
Prevalence of naturally occurring surface gene variants of hepatitis B virus in nonimmunized surface antigen–negative Chinese carriers (2001) (189)
Pre-existing liver disease is associated with poor outcome in patients with SARS CoV2 infection; The APCOLIS Study (APASL COVID-19 Liver Injury Spectrum Study) (2020) (185)
Implication of non-alcoholic fatty liver diseases (NAFLD) in patients with COVID-19: a preliminary analysis. (2020) (184)
World Gastroenterology Organisation Guideline. Hepatocellular carcinoma (HCC): a global perspective. (2010) (182)
Therapeutic vaccination of chronic hepatitis B patients with virus suppression by antiviral therapy: a randomized, controlled study of co-administration of HBsAg/AS02 candidate vaccine and lamivudine. (2007) (176)
Chemotherapy and bone marrow transplantation for cancer patients who are also chronic hepatitis B carriers: a review of the problem. (1999) (175)
Hepatitis due to Reactivation of Hepatitis B Virus in Endemic Areas Among Patients With Hepatitis C Treated With Direct‐acting Antiviral Agents (2017) (170)
Association of Mortalin (HSPA9) with Liver Cancer Metastasis and Prediction for Early Tumor Recurrence* (2008) (162)
Asian‐Pacific consensus statement on the management of chronic hepatitis B: An update * (2003) (154)
Dynamic programmed death 1 expression by virus-specific CD8 T cells correlates with the outcome of acute hepatitis B. (2008) (151)
A phase II dose‐escalating trial of clevudine in patients with chronic hepatitis B (2004) (148)
Effects of tenofovir disoproxil fumarate in hepatitis B e antigen-positive patients with normal levels of alanine aminotransferase and high levels of hepatitis B virus DNA. (2014) (142)
Impairment of CD4+ cytotoxic T cells predicts poor survival and high recurrence rates in patients with hepatocellular carcinoma (2013) (142)
Phase 3 randomized, open-label, multicenter study of tremelimumab (T) and durvalumab (D) as first-line therapy in patients (pts) with unresectable hepatocellular carcinoma (uHCC): HIMALAYA. (2022) (130)
Liver failure determines the outcome in patients of acute-on-chronic liver failure (ACLF): comparison of APASL ACLF research consortium (AARC) and CLIF-SOFA models (2017) (122)
Hepatitis B reactivation after chemotherapy: two decades of clinical research (2008) (122)
Expression of hepatocyte-like phenotypes in bone marrow stromal cells after HGF induction. (2004) (113)
Hepatitis B virus (HBV) reactivation after cytotoxic or immunosuppressive therapy — pathogenesis and management (2001) (113)
Erratum: Asian-Pacific consensus statement on the management of chronic hepatitis B: A 2008 update (Hepatology International 10.1007/s12072-008-9080-3) (2008) (110)
Diagnosis and management of acute variceal bleeding: Asian Pacific Association for Study of the Liver recommendations (2011) (108)
Hepatoprotective effects of Coptidis rhizoma aqueous extract on carbon tetrachloride-induced acute liver hepatotoxicity in rats. (2009) (103)
Hepatitis B reactivation in hepatitis B and C coinfected patients treated with antiviral agents: A systematic review and meta‐analysis (2017) (94)
Hepatitis B e Antigen Seroconversion: A Critical Event in Chronic Hepatitis B Virus Infection (2010) (85)
APASL consensus statements and recommendations for hepatitis C prevention, epidemiology, and laboratory testing (2016) (83)
Sustained response to peginterferon alfa-2a (40 kD) with or without lamivudine in Asian patients with HBeAg-positive and HBeAg-negative chronic hepatitis B (2008) (82)
Use of famciclovir to prevent HBV reactivation in HBsAg-positive recipients after allogeneic bone marrow transplantation. (1998) (74)
Efficacy and safety of 3-week response-guided triple direct-acting antiviral therapy for chronic hepatitis C infection: a phase 2, open-label, proof-of-concept study. (2016) (72)
Comparing the safety, tolerability and quality of life in patients with chronic hepatitis B vs chronic hepatitis C treated with peginterferon alpha‐2a (2008) (67)
Clinical practice guidance for hepatology and liver transplant providers during the COVID-19 pandemic: APASL expert panel consensus recommendations (2020) (66)
APASL HCV guidelines of virus-eradicated patients by DAA on how to monitor HCC occurrence and HBV reactivation (2019) (65)
A case-controlled study on the use of HBsAg-positive donors for allogeneic hematopoietic cell transplantation. (2000) (59)
A new and sensitive method for the quantification of HBV cccDNA by real-time PCR. (2002) (57)
Clearance of persistent hepatitis B virus infection in Chinese bone marrow transplant recipients whose donors were anti-hepatitis B core- and anti-hepatitis B surface antibody-positive. (1998) (56)
Management of COVID-19 in patients after liver transplantation: Beijing working party for liver transplantation (2020) (56)
Telbivudine plus pegylated interferon alfa-2a in a randomized study in chronic hepatitis B is associated with an unexpected high rate of peripheral neuropathy. (2015) (53)
Immune system and hepatitis B virus infection. (2005) (51)
Dynamic decrease in PD-1 expression correlates with HBV-specific memory CD8 T-cell development in acute self-limited hepatitis B patients. (2009) (50)
Hepatitis B reactivation in hepatitis B and C coinfected patients treated with antiviral agents: a systematic review and meta-analysis (2017) (50)
Clinical Characteristics Predicting Progression of COVID-19 (2020) (50)
Enhanced Detection of Early Hepatocellular Carcinoma by Serum SELDI-TOF Proteomic Signature Combined with Alpha-Fetoprotein Marker (2010) (50)
Effect of COVID-19 on patients with compensated chronic liver diseases (2020) (46)
Systemic inflammatory response syndrome in acute‐on‐chronic liver failure: Relevance of ‘golden window’: A prospective study (2017) (44)
103 VIROLOGICAL AND BIOCHEMICAL RESPONSE IN PATIENTS WITH HBEAG-NEGATIVE CHRONIC HEPATITIS B TREATED WITH PEGINTERFERON ALFA-2A (40KD) WITH OR WITHOUT LAMIVUDINE: RESULTS OF 4-YEAR FOLLOW-UP (2008) (40)
Drug-Induced Acute-on-Chronic Liver Failure in Asian Patients. (2019) (38)
Response to antiviral treatment in patients infected with hepatitis B virus genotypes E–H (2009) (38)
Liver Intestine-Cadherin (CDH17) Haplotype Is Associated with Increased Risk of Hepatocellular Carcinoma (2006) (38)
Pharmacokinetics of pitavastatin in subjects with Child-Pugh A and B cirrhosis. (2005) (36)
Will Sofosbuvir/Ledipasvir (Harvoni) Be Cost-Effective and Affordable for Chinese Patients Infected with Hepatitis C Virus? An Economic Analysis Using Real-World Data (2016) (35)
HEPATITIC GRAFT-VERSUS-HOST DISEASE AFTER HEMATOPOIETIC STEM CELL TRANSPLANTATION: CLINICOPATHOLOGIC FEATURES AND PROGNOSTIC IMPLICATION (2004) (34)
Life events and daily hassles in patients with atypical chest pain. (1996) (33)
917 ON-TREATMENT MONITORING OF HBsAg LEVELS TO PREDICT RESPONSE TO PEGINTERFERON ALFA-2A IN PATIENTS WITH HBeAg-POSITIVE CHRONIC HEPATITIS B (2009) (33)
924 INCREASING RATES OF HBsAg CLEARANCE AND SEROCONVERSION IN PATIENTS WITH HBeAg-NEGATIVE DISEASE TREATED WITH PEGINTERFERON ALFA-2A ± LAMIVUDINE: RESULTS OF 5-YEAR POST-TREATMENT FOLLOW UP (2009) (32)
Lamivudine and Famciclovir resistant hepatitis B virus associated with fatal hepatic failure. (2003) (31)
Primary biliary cirrhosis-associated hepatocellular carcinoma in Chinese patients: incidence and risk factors. (2015) (31)
APASL clinical practice guideline on hepatitis B reactivation related to the use of immunosuppressive therapy (2021) (31)
Treatment of chronic hepatitis B virus infection: An Asia–Pacific perspective (1999) (30)
13 TELBIVUDINE (LDT) PLUS PEG-INTERFERON (PEGIFN) IN HBEAG-POSITIVE CHRONIC HEPATITIS B – VERY POTENT ANTIVIRAL EFFICACY BUT RISK OF PERIPHERAL NEUROPATHY (PN) (2010) (30)
50 Durability of response and occurrence of late response to peginterferon alpha-2a (40KD) [PEGASYS] one year post-treatment in patients with HBeAg-positive chronic hepatitis B (2006) (29)
Hepatitis B Reactivation in Patients Positive for Hepatitis B Surface Antigen Undergoing Autologous Hematopoietic Cell Transplantation (2003) (29)
APASL clinical practice recommendation: how to treat HCV-infected patients with renal impairment? (2018) (29)
Hepatitis B infection in China. (2001) (29)
HBeAg‐positive chronic hepatitis B: why do I treat my patients with pegylated interferon (2009) (28)
Development of predisposition, injury, response, organ failure model for predicting acute kidney injury in acute on chronic liver failure (2017) (27)
Shortening the duration of therapy for chronic hepatitis C infection. (2017) (27)
Hepatitis B virus infection and bone marrow transplantation. (1999) (27)
Transfusion of autologous cytokine-induced killer cells inhibits viral replication in patients with chronic hepatitis B virus infection. (2009) (26)
One‐week ranitidine bismuth citrate‐based triple therapy for the eradication of Helicobacter pylori in Hong Kong with high prevalence of metronidazole resistance (2001) (26)
ANGPTL8 (Betatrophin) is Expressed in Visceral Adipose Tissue and Relates to Human Hepatic Steatosis in Two Independent Clinical Collectives (2017) (26)
Chronic hepatitis B: a global health problem requiring coherent worldwide treatment strategies (2007) (25)
Current treatments for patients with HBeAg‐positive chronic hepatitis B virus infection: a comparison focusing on HBeAg seroconversion (2010) (25)
Clinical trial: a phase II, randomized study evaluating the safety, pharmacokinetics and anti‐viral activity of clevudine for 12 weeks in patients with chronic hepatitis B (2008) (24)
Therapeutic efficacy of Traditional Chinese Medicine 319 recipe on hepatic fibrosis induced by carbon tetrachloride in rats. (2009) (24)
Current issues and future directions in treatment. (2006) (23)
Hepatitis virus infections in patients with cancer (2003) (23)
Advances in immunomodulating therapy of HBV infection (2005) (23)
Treatment of chronic hepatitis B infection‐2017 (2017) (23)
Improvement of glucose and lipid metabolism with pegylated interferon-α plus ribavirin therapy in Chinese patients chronically infected with genotype 1b hepatitis C virus (2015) (23)
Correction to: Acute-on-chronic liver failure: consensus recommendations of the Asian Pacific association for the study of the liver (APASL): an update (2019) (22)
Detection of hepatitis C virus genome in formalin‐fixed paraffin‐embedded liver tissue by in situ reverse transcription polymerase chain reaction (1994) (22)
Features of hepatitis C virus infection, current therapies and ongoing clinical trials in ten Asian Pacific countries (2015) (21)
The Asian Pacific Association for the Study of the Liver clinical practice guidance: the diagnosis and management of patients with autoimmune hepatitis (2021) (20)
Serum Levels of Hepatitis B Surface Antigen Predict Severity of Fibrosis in Patients With E Antigen-Positive Chronic Hepatitis B. (2015) (20)
APASL practical recommendations for the management of hepatocellular carcinoma in the era of COVID-19 (2020) (19)
Use of immunomodulatory therapy (other than interferon) for the treatment of chronic hepatitis B virus infection (2000) (18)
Colonoscopy Demand and Practice in a Regional Hospital over 9 Years in Hong Kong: Resource Implication for Cancer Screening (2006) (17)
Pegylated interferon alpha-2a (40 kDa) in the treatment of chronic hepatitis B (2006) (17)
Current issues and treatment of fulminant hepatic failure including transplantation in Hong Kong and the Far East. (2003) (17)
Evaluation of a new referral system for the management of dyspepsia in Hong Kong: role of open-access upper endoscopy. (2000) (17)
Twelve-week ribavirin-free direct-acting antivirals for treatment-experienced Chinese with HCV genotype 1b infection including cirrhotic patients (2016) (17)
Preemptive adefovir versus lamivudine for prevention of hepatitis B reactivation in chronic hepatitis B patients undergoing chemotherapy (2015) (17)
Uncover the immune biomarkers underlying hepatitis B e antigen (HBeAg) seroconversion: a need for more translational study. (2012) (17)
Synthesis of Liver Associations Recommendations for Hepatology and Liver Transplant Care During the COVID‐19 Pandemic (2020) (16)
Prophylactic lamivudine therapy for hepatitis B patients undergoing immunosuppressive therapy. (2002) (16)
Clevudine for the treatment of chronic hepatitis B virus infection (2005) (16)
Three‐day lansoprazole quadruple therapy for Helicobacter pylori‐positive duodenal ulcers: a randomized controlled study (2001) (15)
Diverse Changes of Circulating Fibroblast Growth Factor 21 Levels in Hepatitis B Virus-Related Diseases (2017) (15)
APASL clinical practice guidance: the diagnosis and management of patients with primary biliary cholangitis (2022) (14)
Letter to the Editor: Obesity, diabetes, non-alcoholic fatty liver disease and metabolic dysfunction associated fatty liver disease are proinflammatory hypercoagulable states associated with severe disease and thrombosis in Covid-19 (2020) (14)
Is vaccination of donor adequate for clearance of hepatitis B virus after bone-marrow transplantation? (1997) (14)
Forty-eight weeks treatment with clevudine 30 mg qd versus lamivudine 100 mg qd for chronic hepatitis B infection: a double-blind randomized study (2010) (14)
95 Peginterferon alfa-2A (40KD) (PEGASYS®) monotherapy is more effective than lamivudine monotherapy in the treatment of HBEAG-negative chronic hepatitis B: 72-week results from a phase III, partially double-blind study of PEGASYS® alone vs PEGASYS® plus lamivudine vs lamivudine (2004) (14)
The Decision for Liver Transplant in Acute on Chronic Liver Failure (ACLF) - First Week is the Crucial Period - Analysis of the Apasl ACLF Research Consortium (AARC) Prospective Data of 1021 Patients (2016) (13)
Impact of metabolic risk factors on the severity and outcome of patients with alcohol‐associated acute‐on‐chronic liver failure (2020) (12)
Persistence of hepatic hepatitis B virus after serological clearance of HBsAg with autologous peripheral stem cell transplantation. (1997) (12)
Reactivation of chronic hepatitis B infection (2002) (12)
Immunoglobulin M and A antibodies to hepatitis C core antigen in chronic hepatitis C virus infection (1994) (11)
ROLE OF LIVER BIOPSY IN THE MANAGEMENT OF LIVER DYSFUNCTION AFTER HEMATOPOIETIC STEM‐CELL TRANSPLANTATION IN A HEPATITIS B VIRUS‐PREVALENT PATIENT POPULATION1 (2003) (11)
Abnormal gastro‐oesophageal reflux in Chinese with atypical chest pain (1996) (11)
Chronic hepatitis B: HBeAg seroconversion after pegylated interferon and nucleos(t)ide analogs (2005) (10)
Non-alcoholic fatty liver disease is a risk factor for occurrence of hepatocellular carcinoma after sustained virologic response in chronic hepatitis C patients: A prospective four-years follow-up study (2021) (10)
A hepatitis B-free generation in China: from dream to reality. (2016) (10)
Treatment of hepatitis B e antigen-negative patients (2007) (10)
Histological changes of concurrent hepatitis C virus infection in asymptomatic hepatitis B virus patients (1998) (10)
CASE REPORT: Histological changes during clearance of chronic hepatitis B virus infection by adoptive immunity transfer (1999) (9)
743 The majority of patients with HBeAg-negative chronic hepatitis B treated with peginterferon alpha-2a (40KD) [PEGASYS®] sustain responses 2 years post-treatment (2006) (9)
Reply to: ‘No evidence for an increased liver uptake of SARS-CoV-2 in metabolic-associated fatty liver disease’ (2020) (9)
Peginterferon–α2a (40 kDa) (Pegasys®) for hepatitis B (2005) (9)
CLINICAL—LIVER, PANCREAS, AND BILIARY TRACT Sustained Response of Hepatitis B e Antigen-Negative Patients 3 Years After Treatment with Peginterferon Alfa-2a (2009) (9)
49 Association between HBeAg seroconversion and sustained HBV-DNA suppression in patients treated with peginterferon alpha-2a (40KD) (PEGASYS) for HBeAg-positive chronic hepatitis B (CHB) (2006) (9)
Does treatment with interferon-based therapy improve the natural history of chronic hepatitis B infection? (2007) (8)
Dynamic assessments of hepatic encephalopathy and ammonia levels predict mortality in acute-on-chronic liver failure (2021) (8)
Immunological approaches to the breakdown of hepatitis B viral persistence. (1998) (8)
Reply to: “NAFLD is a predictor of liver injury in COVID-19 hospitalized patients but not of mortality, disease severity on the presentation or progression – The debate continues” (2020) (8)
Early Viral Kinetics with Telbivudine, Tenofovir or Combination of Both in Immunotolerant Patients with Hepatitis B e Antigen-Positive Chronic Hepatitis B (2014) (6)
PREDICTION OF RESPONSE TO PEGINTERFERON-ALFA IN HBEAG POSITIVE CHRONIC HEPATITIS B: A MODEL BASED ON 721 PATIENTS (2008) (6)
683 ON-TREATMENT HBSAG DECLINE IN HBEAG-NEGATIVE PATIENTS AS A PREDICTOR OF RESPONSE TO PEGINTERFERON ALFA-2A (40KD) THERAPY 3 YEARS POST-TREATMENT: POTENTIAL FOR RESPONSE-GUIDED THERAPY (2008) (6)
1181 A phase III, partially double-blinded study evaluating the efficacy and safety of peginterferon alfa-2A (40KD) (PEGSYS®) alone or in combination with lamivudine vs lamivudine in 546 patients with HBEAG-negative/anti-HBE-positive chronic hepatitis B (2003) (6)
How do we handle the anti‐HBc positive patient? (in highly endemic settings) (2015) (6)
Peginterferon-alpha2a (40 kDa) (Pegasys) for hepatitis B. (2005) (6)
Comparative accuracy of prognostic models for short-term mortality in acute-on-chronic liver failure patients: CAP-ACLF (2021) (6)
‘First week’ is the crucial period for deciding living donor liver transplantation in patients with acute-on-chronic liver failure (2021) (5)
No increase in the occurrence rate of hepatocellular carcinoma in Chinese treated by direct-acting antivirals compared to Interferon after eradication of hepatitis c virus: a long-term follow-up (2017) (5)
Loss of HBsAg in chronic hepatitis B carrier following high‐dose chemotherapy and autologous peripheral blood stem cell rescue for lymphoma (1995) (5)
Complete response of acquired FV inhibitor to rituximab (2015) (4)
HCV in hepatic failure: West and East do not meet (1999) (4)
Hepatitis B vaccination and preemptive treatment of hepatitis B virus in liver transplantation (2006) (4)
47th Annual meeting of the American Association for the Study of Liver Disease, November 1996 (1997) (4)
Reply to: ‘Younger patients with MAFLD are at increased risk of severe COVID-19 illness: A multicenter preliminary analysis’ (2020) (4)
Management of chronic hepatitis B in treatment-experienced patients. (2004) (4)
A dose escalating trial evaluating the safety and antiviral activity of clevudine in patients with chronic HBV infection (2003) (4)
A new magic bullet for chronic hepatitis B infection: is this the end of the story? (2009) (4)
Novel treatment for gastric intestinal metaplasia, a precursor to cancer (2020) (4)
Shortening HCV therapy: science meets public health. (2017) (3)
Novel insights into the association between HLA-DP variants and persistent hepatitis B virus infection: a genome-wide association study. (2010) (3)
Disentangling the lifespans of hepatitis C virus‐infected cells and intracellular vRNA replication‐complexes during direct‐acting anti‐viral therapy (2020) (2)
Management of chronic hepatitis B e antigen-negative disease: another step forward. (2012) (2)
Impact of compensated cirrhosis on survival in patients with acute-on-chronic liver failure (2021) (2)
Treatment of immunosuppressed chronic hepatitis B patients. (2005) (2)
438 Continued safety and efficacy of adding adefovir dipivoxil (ADV) to ongoing lamivudine (LAM) therapy in compensated chronic hepatitis B (CHB) patients with YMDD variant HBV: 2 year results (2004) (2)
The 10-year chronic liver disease spectrum evolution in China: experience from the largest tartiary special hospital with 21382 liver biopsy cases (2018) (2)
World gastroenterology organisation practice guideline - hepatitis B September 2008 (2009) (2)
Evaluation of a new referral system for the management of dyspepsia in Hong Kong: Role of open‐access upper endoscopy (2000) (2)
Treatment of chronic hepatitis B virus infection: an Asia-Pacific perspective [see comments] (1999) (2)
Hepatitis B virus genotypes and response to interferon alpha treatment in chronic hepatitis B. (2001) (2)
Erratum: Effects of tenofovir disoproxil fumarate in hepatitis B e antigen-positive patients with normal levels of alanine aminotransferase and high levels of hepatitis B virus DNA (Gastroenterology (2014) 146 (1240-1248)) (2015) (2)
Impact of compensated cirrhosis on survival in patients with acute-on-chronic liver failure (2021) (2)
Portal Hemodynamics Predicts the Outcome in Severe Alcoholic Hepatitis Presenting as Acute-on-Chronic Liver Failure (2016) (1)
Idiopathic multitudinous fundic gland polyposis: A new disease and a management dilemma (2021) (1)
Are immune-checkpoint inhibitors immunosuppressive to hepatitis B virus? (2022) (1)
Treatment of hepatitis B and C following nonliver organ transplants (2003) (1)
[487] PREDICTORS OF HBsAg REDUCTION IN HBsAg- NEGATIVE CHRONIC HEPATITIS B PATIENTS TREATED WITH PEGINTERFERON a-2a (40 kD) ALONE OR IN COMBINATION WITH LAMIVUDINE (2007) (1)
Better Survival in Patients with Hepatitis E Virus C.F. to Other Acute Insults Causing Acute-on-Chronic Liver Failure (ACLF) – APASL-ACLF Research Consortium (AARC) Database (2016) (1)
48 Weeks pegylated interferon alfa-2a is superior to 24 weeks of pegylated interferon alfa-2b in achievingHBeAg seroconversion in chronic hepatitis B infection (2006) (1)
Interferon for Chinese patients with chronic hepatitis B e antigen-positive diseases—the controversy arises again? (2014) (1)
Dynamic AARC-AKI score determines Extrarenal Organ Failures and Bacterial Infection in patients with Acute on Chronic Liver Failure (2017) (1)
Clearance of chronic hepatitis B infection after bone marrow transplant (1995) (1)
Etiology, time frame and spectrum of decompensation in 6236 patients of cirrhosis liver across Asia: a multinational study from APASL ACLF Research Consortium (AARC) (2017) (1)
Prednisolone Therapy Accelerated Recovery of Severe Drug-Induced Liver Injury: A Prospective Randomized Controlled Study (2021) (1)
Reactivation of chronic hepatitis B viral infecion after bone marrow transplantation. (1996) (1)
1160 Analysis of early viral kinetics and T-cell reactivity in relation to HBEAG seroconversion during the first 12 weeks of antiviral therapy for chronic hepatitis B (2003) (1)
491 Peginterferon alpha-2a (40KD) (PEGASYS) reverses cirrhosis, improves fibrosis and slows progression of fibrosis in patients with HBeAg-positive or HBeAg-negative chronic hepatitis B (CHB) (2006) (1)
Acute variceal bleeding portends poor outcomes in patients with acute-on-chronic liver failure: a propensity score matched study from the APASL ACLF Research Consortium (AARC) (2022) (1)
Occult Hepatitis B and Risk of Reactivation after Hepatitis C Treatment with Direct-Acting Antivirals-reply (2016) (1)
Long-term disease progression in chronic hepatitis B Chinese patients with comorbid nonalcoholic fatty liver disease (2017) (1)
Erratum to “Does treatment with interferon-based therapy improve the natural history of chronic hepatitis B infection?” [J Hepatol 46 (2007) 6–8] (2007) (0)
FRI-161-Complication is a major risk factor for mortality of cirrhotic hepatitis B virus-related acuted-on-chronic liver failure patients: A multi-national study from Asian-pacific region (2019) (0)
Clearance of persistent hepatitis B virus infection in Chinese bone marrow transplant (BMT) recipients from anti-HBc+/anti-HBs+ BMT donors. (1998) (0)
Title Asian-Pacific consensus statement on the management ofchronic hepatitis B : a 2008 update (2008) (0)
Efficacy of famciclovir to prevent HBV reactivation in HBsAg positive recipients after bone marrow transplantation (1997) (0)
Identification of biomarkers for the prediction of HBV related HCC by integrated proteomics (2007) (0)
Reduction of hepatitis due to HBV reactivation in HbsAg positive patients undergoing allogeneic bone marrow transplantation with pre-emptive lamuvidine treatment. (2001) (0)
THU-045-Natural history of sepsis, organ failure and organ dysfunction in critically ill patients with acute on chronic liver failure (2019) (0)
HBV infection in immunocompromised patients (2005) (0)
A randomised study of lamivudine for prevention of HBV reactivation in HbsAg seropositive patients undergoing cytotoxic chemotherapy. (2002) (0)
[514] PREDICTION OF LIVER HISTOPATHOLOGY BY NON-INVASIVE MODELS IN HBeAg-POSITIVE AND HBeAg-NEGATIVE CHRONIC HEPATITIS B (2007) (0)
Effect of one marrow transplantation on hepatitis B infection. (1997) (0)
Tenofovir is more potent over entecavir in reducing the viral load in patients of hepatitis B reactivation presenting as Acute on Chronic Liver Failure (ACLF)-Results of multination study from APASL-ACLF Research Consortium (AARC) (2018) (0)
Clinical and serological outcome of allogeneric bone marrow transplantation from HBsAg positive doners (1996) (0)
P.112 Response is sustained two years post-treatment in the majority of patients with HBeAg-negative chronic hepatitis B treated with peginterferon alpha-2a (40KD) [PEGASYS®] (2006) (0)
Free Paper Session I (2006) (0)
Reply to: ‘NAFLD or comorbidities, that is the question’ (2020) (0)
The risk predictive values of UK-PBC and GLOBE scoring system and performance of biochemical response criteria in Chinese patients with primary biliary cholangitis (PBC) on ursodeoeycholic acid (2018) (0)
O.046 Treatment of hepatitis B e antigen positive disease (2006) (0)
Validation of TPPM Score in predicting short-term survival in HBV-ACLF patients: a multi-national study from APASL ACLF Research Consortium (AARC) (2017) (0)
Title Advances in immunomodulating therapy of HBV infection (2005) (0)
Hepatocyte-like phenotypes of bone marrow stromal cells after co-culture with damaged liver tissues and intraportal transplantation in cirrhotic liver (2004) (0)
Immune clearance of serum hepatitis B surface antigenaemia following allogeneic bone marrow transplantation: vaccination versus natural immunity (1998) (0)
Reply: (2009) (0)
Reply to author. (2020) (0)
Proteomics of mouse liver from embryo to adult: a lesion for HCC (2007) (0)
THU-279-The prognostic stratification using acute-on-chronic liver failure scoring systems for predicting short-term mortality in patients with alcoholic hepatitis (2019) (0)
P697 SERUM LEVELS OF HEPATITIS B SURFACE ANTIGEN (HBsAg) PREDICT HEPATIC FIBROSIS SEVERITY IN E ANTIGEN-POSITIVE CHRONIC HEPATITIS B (HBeAg+VE CHB) PATIENTS (2014) (0)
Diverse Changes of Circulating Fibroblast Growth Factor 21 Levels in Hepatitis B Virus-Related Diseases (2017) (0)
Higher baseline MAP protects against organ failure in patients of acute on chronic liver failure (ACLF) (2018) (0)
Nonalcoholic steatohepatitis treatment. (2011) (0)
THU-053-Usefulness of lactate-free Asian Pacific Association for The Study of Liver acute-on-chronic liver failure research consortium ACLF score for predicting short-term mortality in patient with alcoholic liver disease (2019) (0)
Interferon for HBeAg-negative chronic hepatitis B: Teaching an old trick to an old dog? (2005) (0)
The use of cytotoxic T-lymphocyte precursor (CTLP) and helper T-lymphocyte precursor (HTLP) frequencies in the prediction of occurrence and severity of graft-versus-host disease after bone marrow transplantation (2000) (0)
Comparing serum alpha-fetoprotein level and SELDI-TOF-MS profiling for diagnosis of hepatocellular carcinoma (2005) (0)
Achieving WHO target of HCV control in Hong Kong: challenges and strategies. (2021) (0)
Effect of bone marrow transplantation on chronic hepatitis B infections (1997) (0)
Bone marrow transplantation and hepatitis B infection (1997) (0)
Mortalin (HSP9A) is an accurate prognostic biomarker for early recurrence of liver carcinoma (2007) (0)
Profile of ACLF cases in Asia: A multicentre study (2018) (0)
What Should Be Done to Re-evaluate Cessation of Nucleos(t)ide Analog Therapy for Chronic Hepatitis B Infection? (2021) (0)
Reply to Yoshioka et al (2020) (0)
Etiology and clinical features of patients with drug-induced liver injury diagnosed by liver biopsy (2018) (0)
Reply (2018) (0)
Hepatitis B reactivation after interferon-based therapy versus pan-oral direct acting antiviral agents in chronic hepatitis C patients co-infected with hepatitis B virus: a systematic review and meta-analysis (2016) (0)
Clearance of hepatitis B infection after bone marrow transplantation: role of adoptive immune transfer (1995) (0)
The clinical and histological features of serum hepatitis B antigen clearance after allogeneic bone marrow transplantation (1998) (0)
A phase I/II dose escalating trial evaluating safety, tolerability, pharmacokinetics and antiviral activity of clevudine in patients chronically infected with HBV (2003) (0)
682 HBVDNA SUPPRESSION INDUCED BY PEGINTERFERON ALFA-2A (40KD) BUT NOT BY LAMIVUDINE RESULTS IN HBSAG LOSS AND SEROCONVERSION AT 3 YEARS POST-TREATMENT (2008) (0)
OL-015 A pharmacogenomics approach to predict the efficacy of HBeAg-positive chronic hepatitis B patients with pegylated interferon treatment (2008) (0)
Allogeneic bone marrow transplant and hepatitis B infection (1997) (0)
Impact of organ failure in patients with acute on chronic liver failure (ACLF) and the newly defined AARC liver failure score in predicting 90 days survival-results from APASAL-ACLF research consortium (AARC) (2018) (0)
Allogeneic bone marrow transplantation for HbsAg positive patients. (2000) (0)
1171 Molecular epidemiology of hepatitis B virus in patients with HBEAG-negative/anti-HBE-positive chronic hepatitis B from different geographical areas. Data from the PEGASYs® study in HBE-antigen-negative CHB (2003) (0)
712. Treatment of Human and Rat Hepatocellular Carcinomas by Long Term Expression of rAAV-Mediated Transfer of Human TERTC27 Polypeptide (2005) (0)
Correction to: APASL clinical practice guideline on hepatitis B reactivation related to the use of immunosuppressive therapy (2022) (0)
Genetic polymorphisms of liver intestine-cadherin CDH17 are associated with alternative mRNA splicing and increased risk of hepatocellular carcinoma (2005) (0)
492 HBeAg and HBV DNA kinetics in HBeAg clearance with peginterferon alpha-2a (40KD) (PEGASYS) treatment for HBeAg-positive chronic hepatitis B (CHB) (2006) (0)
A case-controlled study on the use of HbsAg positive donors for allogeneic bone marrow transplantation (2000) (0)
Reply to Grifoni et al. (2020) (0)

This paper list is powered by the following services:

Other Resources About George Lau

en.wikipedia.org

What Schools Are Affiliated With George Lau?

George Lau is affiliated with the following schools: